Teva Pharma Industries Ltd ADR (TEVAN)

Mexico


	Symbol		Exchange		Currency
	TEVA		NYSE		USD	Real-time
	TEVAN		Mexico		MXN	Delayed
	TEVAy		TradeGate		EUR	Delayed
	TEVA		Tel Aviv		ILS	Delayed
	TEVAg		Vienna		EUR	Real-time

Currency in MXN

Disclaimer

339.50

0.00(0.00%)

Closed04/10

Fair Value

Day's Range

339.50

339.50

52 wk Range

151.00

377.50

TEVAN Income Statement

Featured here, the Income Statement (earnings report) for Teva Pharma Industries Ltd ADR, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

16,887

16,659

15,878

14,925

15,846

Total Revenues Growth

-7.57%

-1.35%

-4.69%

-6%

+6.17%

Cost Of Revenues

9,351

8,933

8,284

7,952

8,200

Gross Profit

7,536

7,726

7,594

6,973

7,646

Gross Profit Growth

-9.16%

+2.52%

-1.71%

-8.18%

+9.65%

Gross Profit Margin %

44.63%

46.38%

47.83%

46.72%

48.25%

Other Operating Expenses, Total

4,820

4,671

4,515

4,311

4,466

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-9.89%	-3.09%	-3.34%	-4.52%	+3.6%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,010	997	967	838	953
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	3,806	3,671	3,528	3,445	3,498
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4	3	20	28	15

Operating Income

2,716

3,055

3,079

2,662

3,180

Operating Income Growth

-7.84%

+12.48%

+0.79%

-13.54%

+19.46%

EBIT Margin %

16.08%

18.34%

19.39%

17.84%

20.07%

Net Interest Expenses

-781

-797

-891

-920

-961

Net Interest Expenses Growth

+11.35%

-2.05%

-11.79%

-3.25%

-4.46%

Interest Expense, Total

-822

-901

-891

-930

-1,029

Interest And Investment Income

41

104

-

10

68

Other Non Operating Expenses, Total

-54

101

-67

-25

-94

EBT, Excl. Unusual Items

1,881

2,359

2,121

1,717

2,125

Gain (Loss) On Sale Of Assets

49

19

58

64

28

Other Unusual Items, Total

-3,010

-1,897

-1,289

-2,732

-1,964

EBT, Incl. Unusual Items

-1,279

-4,267

667

-3,142

-622

EBT, Incl. Unusual Items Growth

+52.04%

-233.62%

+115.63%

-571.06%

+80.2%

EBT, Incl. Unusual Items Margin

-7.57

-25.61

4.2

-21.05

-3.93

Income Tax Expense

-278

-168

211

-643

-7

Net Income to Company

-1,001

-4,099

456

-2,499

-615

Minority Interest

2

109

-39

53

56

Net Income

-999

-3,990

417

-2,446

-559

Net Income Growth

+53.53%

-299.4%

+110.45%

-686.57%

+77.15%

Net Income Margin %

-5.92%

-23.95%

2.63%

-16.39%

-3.53%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-999

-3,990

417

-2,446

-559

Basic EPS - Continuing Operations

-0.92

-3.64

0.38

-2.2

-0.5

Basic EPS - Continuing Operations Growth

+61.03%

-297.94%

+110.38%

-682.34%

+77.33%

Diluted EPS - Continuing Operations

-0.92

-3.64

0.38

-2.2

-0.5

Diluted EPS - Continuing Operations Growth

+61.04%

-297.94%

+110.38%

-682.34%

+77.31%

Basic Weighted Average Shares Outstanding

1,091

1,095

1,102

1,110

1,119

Diluted Weighted Average Shares Outstanding

1,091

1,095

1,107

1,110

1,119

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

4,438

4,612

4,409

3,970

4,333

EBITDA Growth

-7.33%

+3.92%

-4.4%

-9.96%

+9.14%

EBITDA Margin %

26.28%

27.68%

27.77%

26.6%

27.34%

EBIT